Add BrightSurf on Google Email

A potential therapy to reduce the side effects of a chemotherapy

Scientists have identified a potential therapy to reduce the side effects of cisplatin chemotherapy, which can cause kidney toxicity and neuropathic pain. Istradefylline, an approved Parkinson's disease drug, has been found to mitigate these harmful effects while preserving cisplatin's anti-tumor properties.

SourceINSERM (Institut national de la santé et de la recherche médicale)·JournalJournal of Clinical Investigation·DateNov 15, 2022

New onset chronic kidney disease in people with diabetes highest among ethnic, racial minorities

A study published in the New England Journal of Medicine found that new onset CKD rates are higher among Native Hawaiian/Pacific Islander, Black, American Indian/Alaska Native, and Hispanic/Latino populations compared to white persons with diabetes. The rate declined from 8% in 2015-2016 to 6.4% in 2019-2020.

SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·TypeData/statistical analysis·DateOct 31, 2022

Researchers examine what happens when patients can choose concurrent dialysis and hospice care

A retrospective cross-sectional study found that VA-financed hospice services were associated with higher rates of concurrent dialysis among veterans with end-stage kidney disease. Patients who received VA-financed hospice services lived approximately 43 days after stopping dialysis, compared to just four days for those who stopped dia...

SourceBrigham and Women's Hospital·JournalJAMA Health Forum·TypeObservational study·DateOct 21, 2022

Providence study reveals high incidence of chronic kidney disease in diabetes beset by disparities

A study reveals a high incidence of chronic kidney disease among adults with diabetes, particularly affecting Native Hawaiian/Pacific Islander, Black, American Indian/Alaska Native, and Hispanic/Latino(a) groups. The rate of new onset CKD was higher in these groups by approximately 60%, 40%, 33%, and 25% compared to White persons with ...

SourceProvidence Health & Services·JournalNew England Journal of Medicine·TypeData/statistical analysis·DateOct 12, 2022

New technology offers pathways to finding treatments for kidney disease

Researchers at Washington University have developed a hydrogel system that preserves biochemistry and mechanical environments of cultured podocyte cells. This allows researchers to identify new ways to control mechanisms used by cells to heal themselves, potentially leading to therapies for currently incurable diseases.

SourceWashington University in St. Louis·JournalScience Advances·TypeExperimental study·DateAug 31, 2022

Oncotarget | Kinase activity in renal cell carcinoma, benign renal tissue and in response to tyrosine kinase inhibitors

Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.

SourceImpact Journals LLC·JournalOncotarget·TypeData/statistical analysis·DateAug 17, 2022

Aldosterone linked to increased risk of chronic kidney disease progression and end-stage kidney disease

Higher aldosterone concentrations are associated with lower eGFR, lower potassium levels in blood, and higher potassium and protein concentrations in urine. The risk of CKD worsening was independent of diabetes status. Finerenone may help prevent CKD progression by targeting aldosterone's action.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·TypeObservational study·DateAug 8, 2022

Chinese Medical Journal review explores the role of macrophages in the progression of acute kidney injury to chronic kidney disease

A recent review article highlights the crucial role of macrophages in the progression from acute kidney injury (AKI) to chronic kidney disease (CKD). The study suggests that targeting specific signaling pathways and altering macrophage activation can prevent renal fibrosis and CKD. Therapeutic strategies such as clodronate liposomes an...

SourceCactus Communications·JournalChinese Medical Journal·TypeLiterature review·DateJun 20, 2022

Study: Black kidney transplant patients exhibit faster clearance rates of key immunosuppressive medicine tacrolimus

A new study found that Black kidney transplant recipients exhibit a faster clearance rate of tacrolimus, an immunosuppressive drug. The study suggests that considering both sex and race when dosing tacrolimus may reduce adverse effects and enhance transplant outcomes.

SourceUniversity at Buffalo·JournalPharmacotherapy The Journal of Human Pharmacology and Drug Therapy·DateApr 18, 2022

Low-dose lithium may slow kidney aging

Researchers at The University of Toledo found that low-dose lithium acts as a powerful anti-aging agent in the kidneys by blocking GSK3-beta, an enzyme associated with cellular aging. Studies showed improved kidney function and reduced albuminuria in mice and psychiatric patients treated with lithium.

SourceUniversity of Toledo·JournalJournal of Clinical Investigation·TypeExperimental study·DateApr 12, 2022

Gene variants increase risk of kidney failure in Black veterans with COVID-19: study

A new study published in JAMA Internal Medicine has found that gene variants increased the risk of acute kidney injury and death in African American veterans hospitalized with COVID-19. The study, which analyzed data from over 850,000 diverse veterans, identified APOL1 variants as a key contributor to this increased risk.

SourceVanderbilt University Medical Center·JournalJAMA Internal Medicine·TypeData/statistical analysis·DateFeb 10, 2022

UAB announces first clinical-grade transplant of gene-edited pig kidneys into brain-dead human

Researchers at UAB successfully transplanted genetically modified pig kidneys into a brain-dead human, demonstrating the feasibility of xenotransplantation. The kidneys functioned for 77 hours without immediate rejection, paving the way for potential treatment of thousands suffering from kidney failure.

SourceUniversity of Alabama at Birmingham·JournalAmerican Journal of Transplantation·TypeExperimental study·DateJan 20, 2022

Penn Medicine awarded $14 million NIH grant to apply CAR T immunotherapies to match more patients in need of kidney transplants

A clinical trial will harness synthetic chimeric antigen receptor (CAR) T cells to deplete immune B cells and plasma cells producing donor-specific antibodies, aiming to achieve a compatible kidney match for patients with pre-existing antibodies. The NIH-funded study, led by Penn Medicine, intends to begin enrolling patients in 2022.

Fewer patients sought treatment for kidney failure in early months of COVID-19 pandemic

A new study found that the COVID-19 pandemic led to a 30% decline in patients seeking treatment for kidney failure, with Black patients experiencing significantly worse kidney function. The decline was attributed to changes in healthcare delivery and may reflect delays in treatment due to fear of infection or logistical barriers.

SourceBrown University·JournalJAMA Network Open·TypeObservational study·DateOct 13, 2021

National Kidney Foundation, Leading nephrology experts develop roadmap to advance kidney disease research

The National Kidney Foundation has released a research roadmap to accelerate innovations in treatment and increase understanding of kidney disease. The report calls for increased funding in preclinical science, genetics, health equity, and implementation science to tackle the most vexing challenges in kidney disease.

SourceNational Kidney Foundation·JournalAmerican Journal of Kidney Diseases·DateOct 7, 2021

Study examines heart and kidney outcomes of adults with nephrotic syndrome

A new study highlights the high risk of kidney failure and cardiovascular complications in patients with primary nephrotic syndrome, particularly those with focal segmental glomerulosclerosis. Adults with this condition are 19.63 times more likely to develop kidney failure over a median follow-up period of 4.5 years.

SourceAmerican Society of Nephrology·JournalJournal of the American Society of Nephrology·DateJun 18, 2021

Study estimates duration of employment loss experienced by adults with kidney failure

A new study estimates the years of employment loss experienced by working-aged adults with kidney failure, finding that most lost time is due to patients' loss of life expectancy. The study analyzed data from patients initiating dialysis in Taiwan and found that men had a higher rate of employment than women.

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateApr 15, 2021

Waitlist policies may contribute to racial disparities in kidney transplant access

A recent study found that enrolling Black patients on the waitlist with slightly better kidney function could reduce racial disparities in transplant access. This approach aims to bridge the gap between Black and white patients' wait times before kidney failure, ultimately promoting greater equality in transplantation.

SourceAmerican Society of Nephrology·JournalJournal of the American Society of Nephrology·DateFeb 23, 2021